Search
Biogen Inc
BIIBAdd to Watchlist
199.590USD
+2.400+1.22%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
29.47BMarket Cap
21.35P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.22%
5 Days
+0.46%
1 Month
+3.01%
6 Months
+13.19%
Year to Date
+13.41%
1 Year
+58.02%
Key Figures
199.340Open
202.058High
1.35MVolume
21.35P/E TTM
12.24P/E Dynamic
--Dividend TTM
0.91%Turnover Ratio
197.190Prev. Close
198.660Low
222.25MTurnover
18.05P/E Static
1.58P/B
0.00%Div Yield TTM
4.77%ROA
205.97052wk High
1.03Volume Ratio
1.63BNet Profit
147.60MShares
9.3497EPS TTM
0.20Beta
7.70%ROE
121.05052wk Low
1.72%Amplitude
67.81%Gross Margin
29.47BMarket Cap
1.07Reward/Risk
2.00%Risk Rate
TradingKey Stock Score of Biogen Inc
Currency: USD Updated: 2026-06-24Key Insights
Biogen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 220.75.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biogen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Biogen Inc Highlights
StrengthsRisks
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Fairly Valued
The company’s latest PE is 21.35, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 144.76M shares, decreasing 2.68% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 5.84K shares of this stock.
Analyst Rating
Based on
38
analysts
Buy
Current Rating
220.747
Target Price
+12.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biogen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biogen Inc Info
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Ticker SymbolBIIB
CompanyBiogen Inc
CEOViehbacher (Christopher A)
Websitehttps://www.biogen.com/
Related Instruments
+0.90%
+0.82%
+0.08%
-0.14%
+0.88%
+0.83%
+1.27%
-0.02%
+0.09%
-2.71%
+1.45%
-0.89%
-1.86%
-0.65%
+0.41%
0.00%
+0.87%
+1.80%
-0.11%
-0.76%Popular Instruments
FAQs
What is the current price of Biogen Inc (BIIB)?
The current price of Biogen Inc (BIIB) is 199.59.
What is the symbol of Biogen Inc?
The ticker symbol of Biogen Inc is BIIB.
What is the 52-week high of Biogen Inc?
The 52-week high of Biogen Inc is 205.97.
What is the 52-week low of Biogen Inc?
The 52-week low of Biogen Inc is 121.05.
What is the market capitalization of Biogen Inc?
The market capitalization of Biogen Inc is 29.46B.
Is Biogen Inc (BIIB) currently rated as Buy, Hold, or Sell?
According to analysts, Biogen Inc (BIIB) has an overall rating of Buy, with a price target of 220.75.
What is the Earnings Per Share (EPS TTM) of Biogen Inc (BIIB)?
The Earnings Per Share (EPS TTM) of Biogen Inc (BIIB) is 8.83.
